Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
it's an exciting stock at these levels. i bought a ton of cbiif a while ago and that stock exploded. maybe epwcf does the same
I bought in today. Looks exciting. Another CBIIF in the making? Next weeks news could get it really going
BCRX BioCryst Announces FDA Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent Attacks in Hereditary Angioedema Patients. 7500 HAE pts in US. Co expects 60% switchover from injection to oral. $500k per pt per y. $2.25 billion in annual revenues
Anyone own TZPC? Wow
Investors didn’t seem to like the deal. Maybe longer term it’s good for sage but the reaction was negative Friday
SAGE gets over a billion from biogen
https://www.thestreet.com/investing/sage-biogen-biib-depression-drug-development
RVNC FDA stated they are actively working to define an approach for scheduling outstanding inspections, once safe travel may resume and based on public health need and other factors
$RVNC FDA Defers Approval of DaxibotulinumtoxinA for Injection in Glabellar Lines Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspection
Pfizer & BioNTech final results on #covid19 vaccine phase 3: *95% effective*
170 cases in trial
-162 among placebo group
-8 on vaccine
10 severe cases
-9 on placebo
-1 on vaccine
94% efficacy for those 65+
Fatigue, headache after 2nd shot
Plan to submit to FDA within days
Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock
This is a stock that has had big moves, both up
And down over the years
FPRX Announces Bemarituzumab Plus Chemotherapy Demonstrates Significant Progression-Free and Overall Survival Benefit
All 3 efficacy endpoints in the Global Phase 2 FIGHT trial met pre-specified statistical significance
https://www.businesswire.com/news/home/20201110006186/en/Five-Prime-Announces-Bemarituzumab-Plus-Chemotherapy-Demonstrates-Significant-Progression-Free-and-Overall-Survival-Benefit-Compared-to-Placebo-Plus-Chemotherapy-in-Front-Line-Advanced-Gastric-and-Gastroesophageal-Junction-Cancer
SUPN receives Refusal to File (RTF) letter for its NDA for SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations (“on-off” episodes) in Parkinson’s disease.
AFMD and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers (ICE®) for Multiple Cancer Targets.
$AFMD to revive $60M upfront and up to an additional $2B in future milestones
RETA Positive Results From Year 2 of the Pivotal Phase 3 CARDINAL Study of Bardoxolone Methyl in Patients with Alport Syndrome.
To proceed with the submission of an NDA for full marketing approval in Q1
https://www.reatapharma.com/press-releases/reata-announces-positive-results-from-year-2-of-the-pivotal-phase-3-cardinal-study-of-bardoxolone-methyl-in-patients-with-alport-syndrome/
Pfizer said it developing coronavirus vaccine was 90% effective i
https://www.thestreet.com/investing/pfizer-says-covid-19-vaccine-is-90-effective-shares-surge?puc=yahoo&cm_ven=YAHOO&yptr=yahoo
I may be wrong but didn’t the fda advisory committee originally overwhelmingly give Provenge the thumbs up and then the fda issued the CRL? I remember owning the stock before the committee hearing, the stock exploded after the thumbs up and then it tanked after CRL
I can’t imagine BIIB not getting a CRL
Non binding?
BIIB FDA panel votes 7 to 0 against effectiveness of 103 study
About $7.82 a share which isn’t much of a premium. I think their shareholders will be very disappointed
GBT -20% postmarket after third-quarter sales of its lone drug Oxbryta missed the lowest analyst estimate.
BBG data show expectations were for $44.9 million in 3Q, they reported $36.9 million
APLS and Sobi Collaboration for Global Co-development and Ex-US Commercialization of Systemic Pegcetacoplan in Rare Diseases with Urgent Need for New Treatments.
$APLS to receive $250M upfront.
LLY drug for covid fails to help
https://www.lilly.com/news/stories/statement-activ3-clinical-trial-nih-covid19
a lot of volume coming in
Looks interesting. Any price targets? It’s had a big run. Too late to jump in?
$ENDP acquires $BSTC for $88.50/share
GLPG report that no signal of activity was observed in the topline results in their ROCCELLA Phase 2 trial with GLPG1972/S201086.